Homepage
Precinct footprint 280,000sqm
of health and life science infrastructure within 39ha development zone
Footnote: Includes PAH facilities
~A$90bn commercial sales derived from BRIJ innovations since 2006 to present
Source: Based on publicly available revenue data for TRI partners, including Gardasil sales, using March 2025 exchange rates
A$35m+
annual royalties from innovations at BRIJ
Source: Estimated collective revenue DPI, UQ, Feb 2025
A$270m+ annual R&D investment currently flowing through organisations at BRIJ
Source: Estimated collective investment UQ, QUT, DPI, DETSI, TRI, CSIRO, PAH, Feb 2025
A$400m+ funding raised by BRIJ startups from seed to growth stages (2021-2025)
Source: PAH, ESP, UQ, TRI, TFS, UQ, TRI, QUT
~13k+ scientists, clinicians, support staff* & students on site^
Source: *PAH, ESP, UQ, TRI and Thermo Fisher Scientific ^UQ, QUT and Griffith/ACU
200+ active clinical trials
Source: UQ, TRI, QUT at Feb 2025
719k+ patient services provided annually by Princess Alexandra Hospital
Source: PAH, Feb 2025
About page
BRIJ by the numbers
Source: SciVal citations 2022–2024, Dec 2024
Why Queensland
3 x tier-1 universities
Including QUT, Griffith and UQ (a global top 50 ranked institution), offering access to elite research and talent
Sources: topuniversities.com/universities/university-queensland
60% more cost-effective
clinical trials than the US thanks to Australia’s 43.5% R&D Tax Incentive, maximising investor capital efficiency and accelerating ROI timelines
Source: BEDA State of the City 2025, Aug 2025
~3x faster clinical trials
in Australia compared to the US and ~2x faster than the UK for Phase I studies, accelerating time-to-market for new therapeutics
Source: statedevelopment.qld.gov.au/team-qld/clinical-trials, Jul 2024
32 direct international connections
to Asia, Middle East, Oceania and North America, providing round-the-clock global market access via Brisbane International Airport
Source: bne.com.au, Feb 2025
13th country in the world by GDP
Australia’s economic strength has supported Queensland’s two decades of growth at rates surpassing the national average
Source: ATIC Why Australia Benchmark Report, 2024; TIQ Invest in Queensland prospectus, Nov 2024
A$569m
Queensland biomedical exports
Source: statedevelopment.qld.gov.au/industry/critical-industry-support/biomedical, May 2025
A$13.3bn
Queensland agriculture and food exports (2023-24)
Source: daf.qld.gov.au/news-media/campaigns/data-farm/export-trade, Sep 2024
43% higher health index returns
realised by Australian investment landscape versus US health stocks 2014-2024
Source: statedevelopment.qld.gov.au/team-qld/clinical-trials, Jul 2024
Why Brisbane
81% startup ecosystem growth
characterises Brisbane’s entrepreneurial landscape between 2019-2023, creating a wealth of investment targets and validating the region’s innovation climate
Source: 2024 Global Startup Ecosystem Report
19% population surge
predicted over the decade to 2032, cementing Brisbane as Australia’s second-fastest growing capital
Source: Population growth forecasts for major capital cities, ABS 2023
34% forecast economic growth
2021–31 putting Brisbane’s economy on course to reach A$275bn by 2041
Source: 10-year real growth forecast (2021-2031), BEDA State of the City 2025, Aug 2025
36% 10-year health sector growth
forecast from 2021 – 2031
Source: BEDA State of the City 2025, Aug 2025
100+ health and biotech facilities
concentrated in Brisbane’s core provide exceptional research density in a vibrant city environment attractive to high-calibre talent
Source: Population growth forecasts for major capital cities, ABS 2023
